SMA
BIOTU

Sage Mountain Advisors’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Sage Mountain Advisors’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,900
Closed -$510K – 726
2021
Q4 		$510K Hold
50,900
– – 0.06% 298
2021
Q3 		$511K Hold
50,900
– – 0.07% 256
2021
Q2 		$513K Buy
50,900
+22,950
+82% +$230K 0.08% 226
2021
Q1 		$276K Buy
+27,950
New +$287K 0.06% 249

Other funds holding BIOTU

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sage Mountain Advisors's BIOTU Position: Q1 2022 in Review

Sage Mountain Advisors sold out of Biotech Acquisition Company Unit (BIOTU) in Q1 2022, closing a stake of 50,900 shares — an estimated $510K sold.

Sage Mountain Advisors first reported a position in BIOTU in Q1 2021 and held it in 4 quarters. The position peaked at $513K in Q2 2021. 10 funds tracked by Wall St. Rank hold BIOTU as of Q1 2022.

  • Sage Mountain Advisors reported no remaining Biotech Acquisition Company Unit position as of Q1 2022 after selling out during the quarter.
  • Sage Mountain Advisors sold 50,900 Biotech Acquisition Company Unit shares in Q1 2022, an estimated $510K.
  • Sage Mountain Advisors first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 4 quarters.
  • Sage Mountain Advisors's Biotech Acquisition Company Unit position peaked at $513K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q1 2022.

Based on Sage Mountain Advisors's 13F filing for Q1 2022, filed 10 May 2022.